The significant guidance reduction, particularly the swing to negative organic operational growth, signals a worsening demand environment in the core U.S. companion animal business. Traders should expect a negative reaction and watch for further competitive pressure on key franchises like dermatology and parasiticides, as well as potential for additional cost-cutting measures.
Price Chart
Executive Summary
Zoetis reported Q2 2026 adjusted EPS of $1.87, a 1% beat vs. $1.85 consensus, but revenue of $2.468B slightly missed the $2.51B estimate. The company slashed its full-year 2026 guidance, now expecting revenue of $9.12B-$9.32B (organic operational decline of 3%-1%) and adjusted EPS of $6.15-$6.25, down sharply from prior guidance of $6.85-$7.00. The U.S. companion animal business continued to deteriorate, with sales falling 11% due to pet owner price sensitivity and heightened competition, offsetting strength in livestock and international segments. This is a clear bearish signal as the core U.S. franchise is under structural pressure, leading to a significant guidance reduction that will likely drive the stock lower.
Key Financial Metrics
Key Facts
- Q2 2026 revenue flat at $2.468B vs $2.474B YoY; organic operational revenue declined 1%
- Adjusted EPS of $1.87 beat consensus of $1.85 by 1%
- U.S. segment revenue fell 7% to $1.266B; companion animal sales dropped 11%
- Full-year 2026 revenue guidance slashed to $9.12B-$9.32B from $9.68B-$9.96B (organic operational growth of -3% to -1%)
- Full-year 2026 adjusted EPS guidance cut to $6.15-$6.25 from $6.85-$7.00
- Adjusted net income guidance for organic operational growth revised to -9% to -5% from +2% to +6%
- Restructuring charges of $77M in Q2, primarily for employee termination costs under a cost and productivity program
Financial Impact
Full-year revenue guidance cut by ~$560M-$640M at midpoint; adjusted EPS guidance cut by ~$0.70 at midpoint
Risk Factors
- Continued deterioration in U.S. companion animal demand due to pet owner price sensitivity
- Intensifying competition in key categories (dermatology, parasiticides) and generic erosion of Convenia/Cerenia
- Execution risk on cost restructuring program; potential for further guidance cuts if trends worsen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001555280-26-000038 |
| Document: zts-20260806.htm | 0001555280-26-000038 |
| Document: 0001555280-26-000038-index-headers.html | 0001555280-26-000038 |
| Document: 0001555280-26-000038-index.html | 0001555280-26-000038 |
| Document: 0001555280-26-000038.txt | 0001555280-26-000038 |
| 8-K Data (Synthetic) | 0001555280-26-000038 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $77.05 $76.29 | ▲ +0.99% | ▲ +1.58% | $68.97 (+10.49%) |
May 20, 2026 19w ago | 8-K | $79.98 $78.71 | ▼ −1.59% | ▼ −2.13% | $68.97 (−13.77%) |
May 13, 2026 20w ago | Insider Cluster | $75.24 $79.57 | ▲ +5.76% | ▲ +6.61% | $68.97 (−8.33%) |
May 7, 2026 21w ago | 8-K | $87.24 $77.59 | ▲ +11.06% | ▲ +14.20% | $68.97 (+20.94%) |
Apr 8, 2026 25w ago | DEFA14A | $119.65 $112.54 | ▼ −5.94% | ▼ −14.49% | $68.97 (−42.36%) |
Feb 27, 2026 31w ago | Court Ruling | $131.02 $113.27 | ▲ +13.55% | ▲ +5.99% | $68.97 (+47.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access